Clinical Trial Update: VAH Versus VA for Salvage Therapy of R/R-AML [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing VAH versus VA as salvage therapy for relapsed/refractory acute myeloid leukemia, with venetoclax-azacitidine combinations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Venetoclax + Azacitidine
• Venetoclax + Azacitidine + Homoharringtonite

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine | Phase 3 | Status: UNKNOWN